Bisphosphonate inhibits alveolar bone resorption in experimentally-induced peri-implantitis in dogs.
The purpose of this study was to determine the effect of bisphosphonate on alveolar bone resorption in experimentally-induced peri-implantitis in beagle dogs. Experimental peri-implantitis was induced by ligation around the abutments, 6 months after placement of a fixture. Pamidronate (0.6 mg/kg) was injected intramuscularly every 3 days into each of 5 dogs. Another 5 dogs served as the control group and were injected with saline only. Peripheral blood and urine samples were collected every week up to 12 weeks after placement of the ligature. Standard X-rays were taken every week. Urinary deoxypyridinoline (DPD) and serum osteocalcin (OC) were evaluated by ELISA as markers of alveolar bone remodeling. X-ray films were analyzed with a computer image analyzer. After 12 weeks, the bone level was measured after removal of the gingival flap. The distance between the top surface of the fixture and the fundus of the defect was significantly lower in the Pamidronate group (1.59+/-0.55 mm, mean+/-SD) than in the control group (2.41+/-0.48 mm). Bone density analyzed from the X-ray films was significantly higher in the bisphosphonate group (69.2+/-8.7%, mean+/-SD) than in the control group (50.3+/-12.8%) after 2 to 8 weeks compared with the baseline value (100%). OC and DPD levels fluctuated during the experimental period. These findings suggest that bisphosphonate inhibits the progression of alveolar bone resorption during ligature-induced peri-implantitis in dogs.
Shibutani
T
T
Department of Periodontology, Asahi University, Gifu, Japan. shibuya@dent.asahi-u.ac.jp
Inuduka
A
A
Horiki
I
I
Luan
Q
Q
Iwayama
Y
Y
D016301:Alveolar Bone Loss / Q000097:blood / Q000209:etiology / Q000517:prevention & control* / Q000652:urine; D000596:Amino Acids / Q000652:urine; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D003758:Dental Implantation, Endosseous / Q000009:adverse effects; D015921:Dental Implants / Q000009:adverse effects*; D004164:Diphosphonates / Q000627:therapeutic use*; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay; D015675:Osteocalcin / Q000097:blood; D000077268:Pamidronate; D010518:Periodontitis / Q000097:blood / Q000209:etiology* / Q000652:urine; D018709:Statistics, Nonparametric
D000596:Amino Acids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D015921:Dental Implants; D004164:Diphosphonates; D015675:Osteocalcin; C036020:deoxypyridinoline; D000077268:Pamidronate